.header_color .main_menu ul:first-child >li > ul, #top .header_color .avia_mega_div > .sub-menu { border-top-color: red; }

Product Pipeline

Four products are in development for hematology and oncology indications:

  • The company’s lead product, SANGUINATE™, is in clinical testing, focused on treating the comorbidities of sickle cell disease and other disorders caused by ischemia, hypoxia and/or hemolysis.
  • ANF-Rho™ is the result of combining state-of-the-art protein engineering technology with advanced PEGylation techniques to create a novel molecule with a unique mechanism of action. Phase II trials are expected to begin in 4Q/2015.
  • EPEG® is a long-acting 3rd generation PEGylated EPO biologic in clinical development for the treatment of anemia; a comorbidity common with chronic kidney disease and cancer chemotherapy.  Phase I trials are completed.  Prolong retains development and commercialization rights in US, Europe and China. Zydus-Cadila has rights in the rest of the world.
  • PP-403 is a novel cytokine with broad applications in cancer.

error: Not Authorized.